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During orthotopic liver transplantation for fulminant hepatic failure, some patients may develop sudden deterioration of cerebral
perfusion and oxygenation, mainly due to increased intracranial pressure and hypotension, which are likely responsible for
postoperative neurological morbidity and mortality. In the present study, we hypothesized that the favorable effects of hypertonic
saline solution (NaCl 7.5%, 4 mL/kg) infusion on both systemic and cerebral hemodynamics, demonstrated in laboratory and
clinical settings of intracranial hypertension and hemorrhagic shock resuscitation, may attenuate the decrease in cerebral perfusion
pressure that often occurs during orthotopic liver transplantation for fulminant hepatic failure.
METHODS: 10 patients with fulminant hepatic failure in grade IV encephalopathy undergoing orthotopic liver transplantation
with intracranial pressure monitoring were included in this study. The effect on cerebral and systemic hemodynamics in 3 patients
who received hypertonic saline solution during anhepatic phase (HSS group) was examined, comparing their data with historical
controls obtained from surgical procedure recordings in 7 patients (Control group). The maximal intracranial pressure and the
corresponding mean arterial pressure values were collected in 4 time periods: (T1) the last 10 min of the dissection phase, (T2) the
first 10 minutes at the beginning of anhepatic phase, (T3) at the end of the anhepatic phase, and (T4) the first 5 minutes after graft
reperfusion.
RESULTS: Immediately after hypertonic saline solution infusion, intracranial pressure decreased 50.4%. During the first 5 min
of reperfusion, the intracranial pressure remained stable in the HSS group, and all these patients presented an intracranial pressure
lower than 20 mm Hg, while in the Control group, the intracranial pressure increased 46.5% (P < 0.001). The HSS group was the
most hemodynamically stable; the mean arterial pressure during the first 5 min of reperfusion increased 21.1% in the HSS group
and decreased 11.1% in the Control group (P < 0.001). During the first 5 min of reperfusion, cerebral perfusion pressure increased
28.3% in the HSS group while in the Control group the cerebral perfusion pressure decreased 28.5% (P < 0.001). Serum sodium
at the end of the anhepatic phase and 3 hours after reperfusion was significantly higher in the HSS group (153.00 ± 2.66 and
149.00 ± 1.73 mEq/L) than in the Control group (143.71 ± 3.30 and 142.43 ± 1.72 mEq/L), P = 0.003 and P < 0.001 respectively.
CONCLUSION: Hypertonic saline solution can be successfully used as an adjunct in the neuroprotective strategy during orthotopic
liver transplantation for fulminant hepatic failure, reducing intracranial pressure while restoring arterial blood pressure, promoting
sustained increase in the cerebral perfusion pressure.
KEYWORDS: Hypertonic saline solution. Liver transplantation. Reperfusion. Anesthesia. Liver failure. Hepatic encephalopathy.
Intracranial hypertension.
INTRODUCTION
Fulminant hepatic failure (FHF) is a dramatic condition
defined by the development of encephalopathy and
232
CLINICS 2006;61(3):231-8Hypertonic saline solution increases cerebral perfusion pressure
Rocha Filho JA et al.
coagulopathy complicating acute liver injury.1 Fulminant he-
patic failure results in progressive multi-organ failure with a
dramatic impact in the brain. Brain edema is a frequent find-
ing, occurring in up to 80% of patients with grade IV encepha-
lopathy, which ultimately leads to intracranial hypertension
(IH). These conditions are major causes of death in FHF.2,3
Many articles have highlighted the close relationship between
the process that results in brain edema and the pathogenesis
of hepatic encephalopathy (HE).3–5 The management of pa-
tients with FHF is aimed mainly in preventing or reversing
increased intracranial pressure (ICP) associated with support
treatment for other failed organs. The definitive treatment for
patients with FHF is liver replacement.
During orthotopic liver transplantation (OLT), patients
may develop sudden deterioration of cerebral perfusion and
oxygenation, mainly due to the combination of increased in-
tracranial pressure and hypotension, despite aggressive moni-
toring and therapy.6–8 All current treatment modalities are far
from perfect and are associated with serious adverse events:9–
12
 indiscriminate hyperventilation can lead to brain ischemia;
mannitol can cause renal insufficiency and rebound ICP el-
evation; and barbiturates are associated with cardiovascular
depression and prolonged coma.13 Failure to regain con-
sciousness or occurrence of significant postoperative neuro-
logical sequelae despite satisfactory graft function has been
reported,2,14,15 and may be caused by further brain damage
from events occurring during surgery, indicating that peri-
transplantation neuroprotection must be improved.
Contemporary interest in hypertonic saline solution
(HSS) was triggered in 1980, when Velasco et al16 demon-
strated that a bolus injection of 7.5% NaCl (4 mL/kg) rap-
idly restored arterial pressure in severely hemorrhaged
dogs. In animal experiments, HSS consistently has been
shown to reduce ICP consequent to head trauma.17 In clini-
cal trials, the beneficial effects of HSS during hemorrhagic
shock in the presence of intracranial hypertension associ-
ated with systemic hypotension have been noted.18,19 In-
creasing evidence suggests important advantages in HSS
resuscitation, namely, reduction in postresuscitation com-
plications such as renal failure, coagulopathies, and acute
respiratory distress syndrome, possibly by modulation of
the systemic inflammatory response.20–22 The findings that
HSS induces favorable effects on both systemic and cer-
ebral hemodynamics in laboratory and clinical settings of
IH suggest a potential use of this solution during OLT for
FHF. This study presents the preliminary results of the use
of HSS during OLT for FHF.
PATIENTS AND METHODS
Ten patients with FHF undergoing OLT with ICP moni-
toring were included in this study. Systemic and cerebral
hemodynamics effects of HSS infusion in 3 patients (HSS
group) were compared to the data obtained from historical
controls in 7 patients (Control group) who underwent liver
transplants between January 1999 and December 2004.
Only patients who had stage IV encephalopathy and at least
1 episode of IH (defined by ICP >20 mm Hg) before sur-
gery were included in this study. The local hospital ethics
committee (CAPPesq HCFMUSP) approved the study pro-
tocol, and in the HSS group, written informed consent was
obtained from next of kin.
The HSS group received HSS (NaCl 7.5%, 4 mL/kg)
through a central line over a period of 10 minutes at the
beginning of portal vein anastomosis. One of these patients
(patient 2) received a half dose (2 mL/kg) at the beginning
of anhepatic phase to control refractory IH occurred dur-
ing native liver removal, and the remaining 2 mL/Kg was
given at the scheduled time.
Monitoring of ICP was performed by intraparenchymal
device (Camino Systems, San Diego, CA, USA) with con-
tinuous recording during the operation. The maximal ICP
and the corresponding mean arterial pressure (MAP) val-
ues were collected during the following time periods: (T1)
the last 10 min of the dissection phase, (T2) the first 10
minutes at the beginning of anhepatic phase, (T3) at the
end of the anhepatic phase, and (T4) the first 5 minutes
after graft reperfusion. Serum sodium was analyzed at 3
moments: at the beginning of surgery, at the end of
anhepatic phase, and 3 hours after reperfusion.
The aim of management was to maintain a mean ICP
below 20 mm Hg and cerebral perfusion pressure (CPP =
MAP – ICP) above 50 mm Hg. Therapy to control ICP
(mannitol, thiopental, hyperventilation, and head-up posi-
tion at 30°) was instituted whenever the mean ICP became
greater than 25 mm Hg.
Liver transplantation was either performed with pres-
ervation of the recipient’s inferior vena cava during hepa-
tectomy (“piggy-back” technique) or with resection of the
recipient’s retrohepatic inferior vena cava without using
veno-venous bypass (conventional technique). All livers
were hypothermically preserved with iced Belzer UW cold
storage solution (Bristol-Myers Squibb, Princeton, NJ,
USA). Before reperfusion, liver grafts were flushed with
750 mL of lactated Ringer’s solution, via the portal vein.
The hepatic artery was reconstructed after reperfusion.
After data collection, the corresponding CPP for each
time period (T1 – T4) was calculated, and parameter evo-
lution was analyzed as the difference between the time pe-
riods. Data are presented as mean and standard deviation
(Table 1). Statistical analysis was performed by t test; P <
0.05 were taken to be statistically significant.
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RESULTS
In the 3 patients of the HSS group, the ICP decreased
immediately after HSS infusion (36.3 ± 12.5 mm Hg at the
beginning of anhepatic phase vs. 18.0 ± 4.6 mm Hg at the
end of anhepatic phase) (Figure 1). In one patient (patient
2), a half dose of HSS administrated at the beginning of
anhepatic phase lowered a mannitol refractory surge in ICP
from 45 to 19 mm Hg. In this group, the ICP remained con-
sistently below 25 mm Hg from HSS administration
through graft reperfusion (18.0 ± 4.6 mm Hg after HSS in-
fusion vs. 18.0 ± 1.0 mm Hg in the first 5 min after
reperfusion), and no patient developed new episodes of in-
tracranial hypertension (Table 1, Figure 1). During the first
5 minutes after reperfusion, all these patients presented ICP
lower than 20 mm Hg.
In the Control group at the beginning of anhepatic
phase, 3 patients presented IH and a CPP lower than the
critical level of 40 mm Hg, requiring thiopental and man-
nitol therapy. Intracranial pressure and CPP promptly nor-
malized in all treated patients; no other episodes of intrac-
ranial hypertension occurred during the anhepatic phase.
Cerebral perfusion pressure improved slightly during the
anhepatic phase (42.6 ± 11.3 mm Hg at the beginning of
the anhepatic phase vs. 53.3 ± 10.6 mm Hg at the end of
the anhepatic phase), and at the end of this phase, all pa-
tients presented an ICP below 25 mm Hg (Table 1, Fig-
ures 1 and 2). During reperfusion, all patients in this group
presented a rise in ICP (15.9 ± 3.0 mm Hg at the end of
anhepatic phase vs. 23.3 ± 7.4 mm Hg within the first 5
min of reperfusion) (Table 1, Figure 1). Three of these pa-
tients presented IH during reperfusion.
The HSS group presented a greater hemodynamic sta-
bility than the Control group within 5 minutes after graft
reperfusion (MAP, 86.0 ± 5.3 and 61.4 ± 5.4 mm Hg, re-
spectively, P < 0.001) (Table 1, Figure 3). Increased
hemodynamic stability in the HSS group was also docu-
mented by the absence of postreperfusion syndrome, as de-
termined by MAP < 60 mm Hg within the first 5 minutes
after reperfusion (0/3 in the HSS group vs 3/7 in the Con-
trol group).
Cerebral perfusion pressure decreased in both groups
Table 1 - Mean Systemic and Cerebral Hemodynamic Values (mm Hg)
HSS group Control group
Mean ± SD Mean ± SD P
Intracranial pressure end dissection 28.7 ± 6.1 20.6 ± 6.5 not significant
Intracranial pressure early anhepatic 36.3 ± 12.5 20.4 ± 5.9 0.021
Intracranial pressure end anhepatic 18.0 ± 4.6 15.9 ± 3.0 not significant
Intracranial pressure graft reperfusion 18.0 ± 1.0 23.3 ± 7.4 not significant
Mean arterial pressure end dissection 71.7 ± 4.7 77.7 ± 4.4 not significant
Mean arterial pressure early anhepatic 61.7 ± 5.8 63.0 ± 6.1 not significant
Mean arterial pressure end anhepatic 71.0 ± 3.6 69.1 ± 8.8 not significant
Mean arterial pressure graft reperfusion 86.0 ± 5.3 61.4 ± 5.4 <0.001
Cerebral perfusion pressure end dissection 43.0 ± 7.8 57.1 ± 9.5  not significant
Cerebral perfusion pressure early anhepatic 25.3 ± 16.6 42.6 ± 11.3 not significant
Cerebral perfusion pressure end anhepatic 53.0 ± 8.2 53.3 ± 10.6 not significant
Cerebral perfusion pressure graft reperfusion 68.0 ± 6.2 38.1 ± 9.8 0.001
Figure 1 – Intracranial Pressure
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Figure 3 – Mean Arterial Pressure
Figure 2 – Cerebral Perfusion Pressure
at the beginning of the anhepatic phase (41.2% in the HSS
group vs 25.4% in the Control group, NS). Cerebral
perfusion pressure during the anhepatic phase rose 109.5%
in the HSS group vs 25.1% in the Control group, P = 0.059.
The improvement in CPP during the anhepatic phase was
secondary to a decrease in ICP (50.4% in the HSS group
vs 22.1% in Control group) associated with an increase in
MAP (15.1% in HSS group vs 9.7% in the Control group).
Reperfusion was accompanied by a further increase of
28.3% in CPP in the HSS group, while in the Control group
there was a decrease of 28.5%, (P < 0.001) (Figure 2). Dur-
ing graft reperfusion, the HSS group had no ICP variation
along with a MAP increase of 21.1%, whereas in the Con-
trol group the ICP increased 46.5% and MAP decreased
11.1% (Table 2, Figures 1 and 3).
All patients in the HSS group had an intraoperative rise
in serum sodium. Serum sodium at the end of anhepatic
phase and 3 hours after reperfusion was significantly higher
in the HSS group (153.00 ± 2.66 and 149.00 ± 1.73 mEq/
L) than in the Control group (143.71 ± 3.30 and 142.43 ±
1.72 mEq/L), P = 0.003 and P < 0.001, respectively. At 3
hours after graft reperfusion, all patients presented serum
sodium levels close to normality (normal range, 135 – 148
mEq/L) (Figure 4).
In the HSS group, 1 patient developed primary graft
nonfunction and died on the second postoperative day. The
other 2 patients regained consciousness within first week
after OLT without any neurological damage.
In the Control group, there was 3 early deaths. The 2
patients who experienced the lowest CPP during surgery
died; one died 2 hours after reperfusion and the other 8
hours after surgery. The third patient never regained con-
science despite satisfactory graft function and died from
multiple organ failure. The remaining 4 patients regained
conscience after OLT; 1 died from sepsis, and the other 3
made good recoveries.
DISCUSSION
This study evaluated the effects of HSS infusion on cer-
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ebral hemodynamics in patients with FHF during OLT. In
this study, HSS infusion led to an immediate decrease in
ICP and to a marked rise in CPP. In all patients, the ICP
remained consistently below 25 mm Hg from HSS admin-
istration through graft reperfusion, and no patient devel-
oped new episodes of IH. In our study, HSS proved to be
effective in preventing and treating surges in ICP that of-
ten occur in patients with cerebral edema undergoing OLT.
The progressive rise in CPP between HSS administration
and graft reperfusion was supported by the reduction and
maintenance of ICP within security levels combined with
more favorable hemodynamic profiles during reperfusion.
Several centers that perform liver transplantation for
FHF have observed that patients for whom ICP had been
controlled prior transplantation experience recurrence of
increased ICP during surgery despite aggressive monitor-
ing and therapy. Intraoperative care requires judicious use
of fluids and pressors to maintain hemodynamic profiles
and avoid increases of ICP during the entire procedure. A
decrease in CPP is observed during liver transplantation for
FHF when a decrease in blood pressure and cardiac out-
put may be associated with an increase in ICP.6-8 In FHF, a
systemic inflammatory response syndrome occurs in most
of the patients,23 thus complicating hemodynamic and ICP
control during surgery. Failure to regain consciousness de-
spite satisfactory graft function may be caused by further
damage to the brain from these events that frequently oc-
cur during surgery.
Evidence has been accumulating from case series and
small randomized trials, showing that HSS may be an ef-
fective treatment for brain edema and elevated ICP after
head trauma.24,25 The beneficial effects of HSS during
Table 2 - Mean Systemic and Cerebral Hemodynamic Evolution (mm Hg)
HSS group Control group
Mean ± SD Mean ± SD P
Intracranial pressure T2-T1 7.7 ± 17.2 -0.1 ± 7.5 not significant
Intracranial pressure T3-T1 -10.7 ± 10.5 -4.7 ± 4.6 not significant
Intracranial pressure T3-T2 -18.3 ± 8.6 -4.6 ± 4.9 0.011
Intracranial pressure T4-T1 -10.7 ± 6.5 2.7 ± 3.7 0.003
Intracranial pressure T4-T3 0.0 ± 4.0 7.4 ± 5.3 not significant
Mean arterial pressure T2-T1 -10.0 ± 10.4 -14.7 ± 6.3 not significant
Mean arterial pressure T3-T1 -0.7 ± 7.1 -8.6 ± 9.0 not significant
Mean arterial pressure T3-T2 9.3 ± 6.0 6.1 ± 8.3 not significant
Mean arterial pressure T4-T1 14.3 ± 10.0 -16.3 ± 6.8 <0.001
Mean arterial pressure T4-T3 15.0 ± 5.0 -7.7 ± 8.8 0.004
Cerebral perfusion pressure T2-T1 -17.7 ± 23.9 -14.6 ± 11.9 not significant
Cerebral perfusion pressure T3-T1 10.0 ± 15.9 -3.9 ± 6.9 not significant
Cerebral perfusion pressure T3-T2 27.7 ± 11.7 10.7 ± 11.0 not significant
Cerebral perfusion pressure T4-T1 25.0 ± 12.8 -19.0 ± 6.5 <0.001
Cerebral perfusion pressure T4-T3 15.0 ± 7.8 -15.1 ± 4.7 <0.001
T2-T1: difference between beginning anhepatic and end dissection valuesT3-T1: difference between end anhepatic and end dissection valuesT3-T2:
difference between end anhepatic and early anhepatic valuesT4-T1: difference between graft reperfusion and end dissection valuesT4-T3: difference
between graft reperfusion and end anhepatic values
Figure 4 – Serum Sodium
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hemorrhagic shock in the presence of IH associated with
systemic hypotension have also been noted.18,19 Interest-
ingly, it was particularly useful to lower ICP in one of our
patients who presented IH that was refractory to treatment
with mannitol, confirming the already described effective-
ness of HSS in lower ICP when previous therapy to con-
trol IH has failed,24,26–28 pointing to HSS as an alternative
therapy when we did not consider reasonable to repeat a
treatment that was not successful.
The primary mechanism of action of HSS therapy is
rapid osmotic mobilization of cellular water into the blood
volume. Increased cardiac effectiveness occurs because of
a combination of increased preload (venous return) and re-
duced afterload (vasodilatation).29,30 Increased contractility
also has been reported in several studies.31,32 Restoration of
normal intravascular physiology by HSS is achieved
through a potent osmotic gradient across the cell membrane
that causes a net shift of fluid from the cell (mainly en-
dothelial and red blood cells) through the interstitium into
the intravascular space.22,30 This solution also decreases the
swelling of most cell types including neural cells.33 The re-
flection coefficient for sodium chloride is 1.0 (that of man-
nitol is 0.9), and under normal conditions, sodium has to
be transported actively into the cerebrospinal fluid.13,34 The
effect of HSS on the peripheral vasculature and microcir-
culation is generally to induce changes that increase flow.
Capillary perfusion may be further augmented by the abil-
ity of HSS to reverse specific cellular effects of ischemia-
reperfusion.29 The systemic inflammatory response that oc-
curs in ischemia-reperfusion states promotes cytokine re-
lease and increased reactive oxygen metabolites, which ul-
timately cause microvascular damage, all of which can be
attenuated by HSS administration.22 Hyperosmolarity down-
regulates the initial inflammatory activation of neutrophils
and up-regulates immunologic protection provided by
lymphocytes.29 Hepatocellular injury related to the proc-
ess of ischemia-reperfusion may contribute to patient
morbity following liver resection for tumors, trauma, and
transplantation.35 HSS decreases liver tissue damage after
hemorrhagic shock combined with ischemia and
reperfusion of the liver.36 The effect of HSS on systemic
inflammation may help to reduce the severity of intracra-
nial hypertension.22,29
The reperfusion time during OLT is a critical period
characterized by hemodynamic instability and may be as-
sociated with a high frequency of intraoperative cardiovas-
cular complications.37 These complications may range in
severity from a transient hypotension to an acute
hemodynamic deterioration known as postreperfusion syn-
drome.38 In this study, infusion of HSS resulted in avoid-
ance of postreperfusion syndrome in all patients. The ar-
terial blood pressure attained levels even higher than those
determined before the anhepatic phase without the need of
supplementary vasoactive drugs. The net effect observed
was the rise of 28.3% in CPP seen in the HSS group ver-
sus the 28.5% decrease in CPP observed in Control group.
In the present study, a bolus infusion of HSS consist-
ently led to a decrease in the ICP of all patients while main-
taining blood pressure and cardiac output. The restoration
of arterial blood pressure along with reduced ICP are es-
sential conditions for improving intraoperative CPP. The
favorable nature of these effects was more remarkable dur-
ing reperfusion, which has been demonstrated to be a pe-
riod frequently associated with the risk of brain injury sec-
ondary to elevated ICP and low CPP.6–8 In our study, the
beneficial effects of HSS infusion on CPP were sustained
during the remaining surgical time, precluding the need for
additional specific therapeutic measures to maintain CPP
above critical levels.
Infusion of HSS may involve risks because it induces a
rapid change in serum sodium concentration. Although cen-
tral pontine myelinolysis is a hazardous complication, it
is more likely to occur after rapid correction of chronic
hyponatremia.39,40 In FHF, there is no chronic hyponatremia;
therefore, there seems to be no contraindication for its use.
Indeed, hypertonic solutions benefited patients with FHF
by decreasing ICP.5 There has never been a single case,
among more than 1,700 patients treated with HSS, of sei-
zures, intracranial bleeding, central pontine myelinolysis,
or neurological deterioration induced by the HSS.19,28 No
patient in the present series presented neurological com-
plications.
The effects on intracranial, arterial blood, and cerebral
perfusion pressures are most remarkable shortly after the
administration of HSS, but they can also be observed over
several hours and therefore may be useful during OLT un-
til liver function is completely restored. In patient 2, the
half-dose administration at the beginning of the anhepatic
phase was also followed by hemodynamic improvement,
which was sustained even after total vena cava clamping,
suggesting that the potential benefits of HSS administra-
tion prior to the anhepatic phase may result in avoidance
of veno-venous bypass and high-dose hemodynamic
pharmacologic support.
Despite the time factor for the Control group (7 patients
studied in a 6-year period), the technological and clinical
improvements during this period did not change the his-
tory of this disease, and controlling IH remains a major
challenge in FHF that is even now based on classical medi-
cal management and with OLT still being the best option
for these patients.
These results show that HSS can be a useful tool in pa-
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tients with FHF during liver transplantation, as an adjunct
neuroprotective measure that actually improves CPP, espe-
cially when classical measures for neuroprotection against
brain ischemia have failed.
CONCLUSION
Hypertonic saline solution can be successfully used in
patients with fulminant hepatic failure during orthotopic
liver transplantation, reducing intracranial pressure while
restoring arterial blood pressure and cerebral perfusion pres-
sure. Despite the limited number of patients and the ab-
sence of concurrent controls, these data highlight the need
for controlled clinical trials evaluating its use as adjunct
therapy for intracranial hypertension in fulminant hepatic
failure and as first line therapy for neuroprotection during
reperfusion in orthotopic liver transplantation for fulminant
hepatic failure.
RESUMO
Rocha Filho JA, Machado MAC, Nani RS, Rocha JPS, Fi-
gueira ERR, Bacchella T et al. Solução salina hipertônica
aumenta a pressão de perfusão cerebral no transplante do
fígado para hepatite fulminante: resultados preliminares.
Clinics. 2006;61(3):231-8.
Neste estudo testamos a hipótese de que os efeitos benéfi-
cos decorrentes da administração da solução salina
hipertônica (NaCl 7,5%, 4 mL/kg) sobre a hemodinâmica
sistêmica e cerebral na hipertensão intracraniana e no cho-
que hemorrágico, possam atenuar a diminuição da pressão
de perfusão cerebral que freqüentemente acompanha o
transplante do fígado para hepatite fulminante.
MÉTODO: Foram estudados 10 pacientes com hepatite
fulminante em encefalopatia grau IV e monitorização de
pressão intracraniana submetidos ao transplante do fígado.
A hemodinâmica sistêmica e cerebral de 3 pacientes que
receberam solução salina hipertônica durante a fase
anepática (Grupo SSH) foi analisada comparando com os
dados obtidos de 7 pacientes transplantados anteriormente
nas mesmas condições (Grupo Controle). Os valores de
pressão intracraniana máxima e a correspondente pressão
arterial média foram coletados em quatro tempos: (T1) nos
últimos 10 min da fase de disseccão, (T2) nos primeiros
10 minutos da fase anepática, (T3) no final da fase
anepática e (T4) nos primeiros 5 min da reperfusão
RESULTADO: Imediatamente após a infusão da solução
salina hipertônica a pressão intracraniana diminuiu 50,4%.
Nos primeiros 5 min da reperfusão a pressão intracraniana
no Grupo SSH se manteve estável e todos os pacientes apre-
sentavam pressão intracraniana menor que 20 mmHg en-
quanto no Grupo Controle a pressão intracraniana aumen-
tou 46,5% (p<0,001). O Grupo SSH apresentou maior esta-
bilidade hemodinâmica, nos primeiros 5 min da reperfusão
hepática, a pressão arterial média no Grupo SSH aumentou
21,1% e no Grupo Controle diminuiu 11,1% (p<0,001). Nos
primeiros 5 min da reperfusão a pressão de perfusão cere-
bral no Grupo SSH aumentou 28,3% e no Grupo Controle
diminuiu 28,5% (p< 0,001). A natremia no final da fase
anepáica e após 3 horas da reperfusão foi significativamen-
te maior no Grupo SSH (153.00 ± 2.66 and 149.00 ± 1.73
mEq/L) que no Grupo Controle (143.71 ± 3.30 and 142.43
± 1.72 mEq/L), p=0.003 e p< 0.001 respectivamente.
CONCLUSÃO: Estes resultados sugerem que a solução
salina hipertônica pode ser utilizada com sucesso como
medida neuroprotetora no transplante de fígado para
hepatite fulminante, promovendo diminuição efetiva da
pressão intracraniana e estabilidade cardiocirculatória,
proporcionando aumento sustentado da PPC durante a
cirurgia.
UNITERMOS: Solução salina hipertônica. Transplante do
fígado. Reperfusão. Anestesia. Insuficiência hepática.
Encefalopatia Hepática. Hipertensão intracraniana.
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